We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Altimmune Inc | NASDAQ:ALT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.285 | 4.46% | 6.67 | 6.66 | 6.67 | 6.67 | 6.30 | 6.39 | 6,680,417 | 00:59:47 |
“We are all shocked and saddened by Rich’s passing. On behalf of everyone at Altimmune, I extend our heartfelt condolences to his family during this difficult time,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “Rich was not only a brilliant and dedicated leader, but a close friend who brought a sense of wit and joy to our workplace that will be dearly missed by all who had the privilege of working with him. His unique blend of hard work and humor, along with his immeasurable contributions to our Company will continue to inspire us.”
Mr. Eisenstadt’s duties have been assumed and are being performed by Altimmune’s finance and accounting team until his replacement is named. The company has initiated a search for his replacement.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Company Contact:Vipin GargPresident and Chief Executive OfficerPhone: 240-654-1450ir@altimmune.com
Investor Contacts:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com
Julia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
1 Year Altimmune Chart |
1 Month Altimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions